inebilizumab

Led by BioNTech, six biotechs line up for October IPOs
Endpoints
Sat, 09/28/19 - 04:38 pm
IPOs
MRNA
melanoma
inebilizumab
NMOSD
blood cancer
solid tumors
BioNTech
ADC Therapeutics
Viela Bio
Frequency Therapeutics
Aprea Therapeutics
Monopar Therapeutics
Viela Bio Files for $150 Million IPO
CP Wire
Fri, 08/30/19 - 10:05 am
Veila Bio
IPOs
inebilizumab
NMOSD
Viela Bio Files for $150 Million IPO
Fri, 08/30/19 - 09:52 am
Viela Bio
inebilizumab
NMOSD
Viela reports detailed Phase II/III data for rare CNS disorder therapy
BioCentury
Tue, 05/7/19 - 06:55 pm
Viela
inebilizumab
NMOSD
AstraZeneca Spinoff Viela Bio Reports Positive Phase IIb Trial in Rare Disease
BioSpace
Thu, 01/3/19 - 04:13 pm
Viela Bio
AstraZenecal
N-MOmentum
inebilizumab
NMOSD